SimonMed Announces Research Collaboration with Oxford Brain Diagnostics to Leverage Cortical Disarray Measurement (CDM®) in Diagnosing Neurodegenerative Diseases

SCOTTSDALE, Ariz., June. __, 2024 – SimonMed Imaging ("SimonMed"), one of the largest outpatient medical imaging providers and radiology practices in the United States, announces today its research collaboration with Oxford Brain Diagnostics to explore using Cortical Disarray Measurement (CDM) to better diagnose neurodegenerative diseases.

The research will investigate CDM in patients with mild cognitive impairment (MCI) to evaluate for possible Alzheimer's disease and other dementias. We aim to demonstrate the accuracy and efficacy of CDM compared to other diagnostic methods including standard MRI and PET. The research is one of many projects underway at SimonMed to enhance patient care and leverage new technologies for the most accurate and early diagnoses possible.

"Fundamental to many forms of dementia is neurodegeneration, which often signifies disruption of the brain's gray matter. Current brain MRI utilizing conventional sequences has a limited ability to characterize gray matter. This is made even more challenging since gray matter is a thin ribbon of tissue only 2-5 mm thick" said Dr. Lefkowitz, Medical Director of MRI for SimonMed Imaging. "To be successful, the imaging method must have sufficient spatial resolution and sensitivity to microscopic changes in gray matter that accompany neurodegeneration. Oxford Brain Diagnostics has developed a new software analysis tool (FDA 510k pending) that is more sensitive to neuronal degeneration in the brain's gray matter, thereby supporting earlier diagnosis of many forms of neurodegenerative diseases such as Alzheimer's disease, posterior cortical atrophy, and frontotemporal dementia including subtypes."

"Oxford Brain Diagnostics will analyze data from patients and controls scanned at several SimonMed facilities, applying CDM which leverages the diffusion properties of water in the brain's gray matter. Disrupted diffusion can result from tissue degeneration and is an early indicator of several forms of dementia," said Dr. Steven Chance, CEO and Co-Founder at Oxford Brain Diagnostics. "We're seeking to demonstrate the utility of CDM in the assessment of neurodegeneration in an outpatient clinical population.

Establishing this partnership will enable further insights into discovering the important role cortical microstructure will play in a clinical setting with access to standard MRI."

With the advent of new pharmacologic therapies, early and accurate diagnosis of neurodegenerative diseases is more important than ever.

About SimonMed

Headquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient medical imaging providers and radiology practices in the United States. SimonMed has approximately 170 sites across 11 states and over 200 subspecialty-trained radiologists. SimonMed offers the full modality of diagnostic scans, including 3T MRI, CT, ultrasound, 3-D mammography, PET/CT, nuclear medicine, DEXA, X-rays, among others. The company uses the newest, most advanced, diagnostic imaging technologies while maintaining affordability and accessibility. SimonMed is a worldwide leader in the clinical use of AI to improve diagnoses with one of the largest global deployments to enhance early breast cancer detection and in the evaluation of brain disorders. Through its simonONE division, SimonMed is also at the forefront of personalized imaging for the early diagnosis and treatment of disease. For more information, visit simonone.com and simonmed.com.
www.SimonMed.com

About Oxford Brain Diagnostics Ltd

Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company's patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early diagnosis and track progression, of neurodegenerative diseases. Oxford Brain Diagnostics is committed to supporting drug development and helping clinicians around the world in their fight to defeat Alzheimer's and other neurodegenerative diseases.

For more information, visit https://www.oxfordbraindiagnostics.com
Contact: Omar Ehsan, Chief Commercial Officer; omar.ehsan@oxfordbraindiagnostics.com